ArticleBMJ case reports2017
Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.
Article in BMJ case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Anti-obesity medications in children and adolescents: blood pressure and chronic kidney disease implications.Pediatric nephrology (Berlin, Germany) · 2026Review
- Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.Heliyon · 2024Article
- Assessment and management of chronic kidney disease in people living with obesity.Clinical medicine (London, England) · 2023Article
- Current and emerging medications for the management of obesity in adults.The Medical journal of Australia · 2023Review
- Case - Orlistat-induced calcium oxalate crystalluria.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Oxalate crystal-related acute renal injury caused by orlistat: A case report.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- Management of Obesity in Adults with CKD.Journal of the American Society of Nephrology : JASN · 2021Review
- Calcium oxalate crystal deposition in the kidney: identification, causes and consequences.Urolithiasis · 2020Review
- The association of calcium oxalate deposition in kidney allografts with graft and patient survival.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020Article
- Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?Frontiers in endocrinology · 2020Review
- Secondary Oxalate Nephropathy: A Systematic Review.Kidney international reports · 2018Article
- Medical therapy for nephrolithiasis: State of the art.Asian journal of urology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two patients developed kidney failure due to oxalate deposition in the kidney while taking orlistat. Cessation of orlistat was followed by partial recovery of kidney function. The mechanism by which orlistat causes hyperoxaluria and the management of orlistat-induced oxalate nephropathy is reviewed. We suggest that all patients taking orlistat are at risk of this condition, which may develop insidiously and is easily overlooked. Monitoring of kidney function of patients taking orlistat is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.